Pfizer is pursuing pipeline expansions through the Metsera acquisition and a major licensing deal with 3SBio. Find out why ...

Revenue in 2026 will be $59.5 billion to $62.5 billion, roughly in line with Wall Street’s estimate, Pfizer said Tuesday in a ...

Discover why Pfizer (PFE) remains a compelling income opportunity with a 7% yield, robust cash flow, and long-term growth ...

Alongside its cost-cutting strategy, Pfizer has been investing into its cardiometabolic pipeline in a bid to enter the ...

Pfizer Inc. (NYSE:PFE) today provided its full-year 2026 guidance (2) while revising its November 4, 2025 full-year 2025 Revenue guidance (2) and reaffirming all other components of full-year 2025 ...

Pfizer expects 2026 revenue of $59.5 billion to $62.5 billion and adjusted earnings of $2.80 to $3 a share. Wall Street is ...

Pfizer has entered into a global collaboration and license agreement with YaoPharma for the development, manufacturing and commercialization of YP05002, a small-molecule GLP-1 receptor agonist ...

Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026. Keep ...

Fourth-Quarter 2024 Reported (2) Diluted EPS of $0.07 and Adjusted (3) Diluted EPS of $0.63 On Track to Deliver Overall Net Cost Savings of Approximately $4.5 Billion by End of 2025 from Ongoing Cost ...

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced top-line results from their Phase 3 clinical trial to evaluate ...

NEW YORK & BOTHELL, Wash.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Seagen Inc. (Nasdaq: SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will ...